Ipragliflozin is a selective sodium glucose cotransporter 2 inhibitor that increases urinary glucose excretion, and subsequently improves glucolipotoxicity. The article by Takasu et al. demonstrated that the treatment with ipragliflozin decreased pancreatic cells positive for 4-hydroxy-2-nonenal (4HNE), an oxidative stress marker, in obese type 2 diabetes mellitus (DM) db/db mice. Histopathological examination of pancreatic islet cells revealed strong insulin staining, whereas reduced glucagon staining, accordingly pancreatic insulin content tended to be higher in the ipragliflozin 10 mg/kg-treated group compared with the DM-control group. It was demonstrated that ipragliflozin has a protective effect on the pancreas by reducing oxidative stress.